Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04533360 · ClinicalTrials.gov registry record
Prevalence of COVID-19 Antibodies Kingman AZ
A clinical trial, sponsored by Kingman Regional Medical Center.
- Completed
- Registry status
- 566
- Enrollment target
NCT04533360: Completed study, sponsored by Kingman Regional Medical Center.
NCT04533360 is a clinical trial that has completed, run by Kingman Regional Medical Center. The registered enrollment target is 566 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04533360 has completed, sponsored by Kingman Regional Medical Center.
- COMPLETED
- Registry status
- 566 participants
- Enrollment target
Study Summary
The COVID-19 disease outbreak is a historic event that has challenged medical systems in the United States. Currently, most reports of confirmed cases rely on the testing of symptomatic patients. These estimates of confirmed cases miss individuals who have recovered from infection, with mild or no symptoms, and individuals with symptoms who have not been tested due to the limited availability of tests. We are conducting serology testing within the community for SARS-CoV-2-specific antibodies through a serologic test could give insight into past COVID-19 infections within our community.
Primary Outcome
A sample from the population of Kingman AZ will be used to determine the epidemiology of COVID-19 spread throughout Kingman AZ.
Interventions
- DIAGNOSTIC_TEST VITROS Anti-SARS-CoV-2 IgG test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 566 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2021-05-01 |
What the finished NCT04533360 record still lists
NCT04533360 is an observational study that tracks outcomes without assigning an intervention. The registered 566 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which VITROS Anti-SARS-CoV-2 IgG test is the first listed.
NCT04533360 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04533360 about?
NCT04533360 is a clinical study titled "Prevalence of COVID-19 Antibodies Kingman AZ". The COVID-19 disease outbreak is a historic event that has challenged medical systems in the United States. Currently, most reports of confirmed cases rely on the testing of symptomatic patients. These estimates of confirmed cases miss individuals who have recovered from infection, with mild or no s...
What is the current status of trial NCT04533360?
This trial is currently completed. The enrollment target is 566 participants. The study started on 2020-09-28. Estimated completion is 2021-05-01.
What interventions are being tested in trial NCT04533360?
The interventions under investigation include: VITROS Anti-SARS-CoV-2 IgG test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04533360?
This trial is sponsored by Kingman Regional Medical Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05472441 · 568 participants · NA
Linking Education, Produce Provision, and Community Referrals to Improve Diabetes Care (LINK)
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI